LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the third quarter ended September 30, 2019 and is providing a business update.
News
INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer
LA JOLLA, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that reprogram the patient’s innate immune system to fight disease, announced today that the Un… […]
News
INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member
LA JOLLA, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to announce that Edgardo (Ed) Bar… […]
News
INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at 2019 Alzheimer’s Association International Conference (AAIC) Satellite Symposium
LA JOLLA, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments which harness the patient’s innate immune system to fight disease, announced today that the company will be presentin… […]
